📰 Randomized Phase News
Page 13 - Randomized Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Randomized Phase. Real-time updates on events, politics, business and more.
April 28, 2021
- PRESERVE 2 Will Evaluate Survival Benefit of COSELA in 250 Patients with Locally Advanced Unresectable or Metastatic TNBC - RESEARCH TRIANGLE PARK,...
April 6, 2021
Press release content from Business Wire. The AP news staff was not involved in its creation. Bayer to Present New Clinical Data in Indolent non-Hodgkin’s Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021 April 6, 2021 GMT WHIPPANY, N.J.--(BUSINESS WIRE)--Apr 6, 2021-- Bayer will present new research across its oncology portfolio at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, taking place over two weeks on April 10-15 a...
February 3, 2021
ó stata avanzado; presentaciones orales para destacar los resultados de los estudios de fase 3 ACIS, TITAN y SPARTAN SOLO PARA MEDIOS DE COMUNICACIÓN MÉDICOS Y COMERCIALES FARMACÉUTICOS DE LA REGIÓN DE EMEA NO SE PERMITE LA DISTRIBUCIÓN EN EL BENELUX NI EN EL REINO UNIDO Janssen Pharmaceutical Companies de Johnson & Johnson ha anunciado hoy que destacará la solidez de su cartera de tumores sólidos en el Simposio sobre Cánceres Genitourinarios de la Sociedad Americana de Oncología Cl�...
February 2, 2021
Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU Multiple data presentations to show long-term benefit and consistency of ERLEADA® (apalutamide) in advanced prostate cancer; oral presentations to highlight Phase 3 ACIS, TITAN and SPARTAN study results News provided by Share this article Share this article RARITAN, N.J., Feb. 2, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid t...
February 1, 2021
Sacituzumab Govitecan – Another Antibody Drug Conjugate Carving out a Path in Genitourinary Oncology Published 01 February 2021 I have previously discussed the use of antibody-drug conjugates for selective tumor cell intensification of urothelial carcinoma therapy in a Urotoday Clinical Trials Portal article. 1 Similarly, I’ve also focused on enfortumab vedotin before, and enfortumab vedotin is now FDA approved on the accelerated pathway for patients with locally advanced or metastatic u...
December 11, 2020
TMCnet News SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast [December 11, 2020] SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast â Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment â â Statistically Significant Difference of Duration of Immune R...